Clinical Trials Browser

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07368634 2026-01-28

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1/2 Recruiting

18 enrolled

Epstein-Barr Virus Infections

NCT07368153 2026-01-26

IDEP

Phase 2 Not yet recruiting

9 enrolled

Epstein-Barr Virus Infections

NCT07294547 2025-12-19

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Phase NA Recruiting

80 enrolled

Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT02048332 2025-12-16

VSTs

Phase 1/2 Recruiting

750 enrolled

Adenoviridae Infections, Virus Diseases, Epstein-Barr Virus Infections

NCT04664179 2025-12-12

CILESTE

Phase 1 Recruiting

52 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Epstein-Barr Virus Infections

NCT07261215 2025-12-03

Zuberitamab for EBV Infection Post-Allo-HSCT

Phase 2 Not yet recruiting

20 enrolled

Epstein-Barr Virus Infections

NCT05683834 2025-11-21

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Phase 1/2 Active not recruiting

25 enrolled

Herpes Simplex, Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT04925544 2025-10-21

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Phase 2 Active not recruiting

13 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT05831111 2025-09-30

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Phase 1 Active not recruiting

482 enrolled

Infections, Infectious Mononucleosis, Virus Diseases, Epstein-Barr Virus Infections

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

10 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

Phase 1/2 Not yet recruiting

30 enrolled

Infections, Epstein-Barr Virus Infections

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

10 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT06909110 2025-08-14

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Phase 1/2 Recruiting

25 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT03266653 2025-08-08

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Phase 2 Recruiting

20 enrolled

Primary Immunodeficiency Diseases, Epstein-Barr Virus Infections

NCT04013802 2025-08-08

TETRAVI

Phase 1 Recruiting

47 enrolled

Adenoviridae Infections, Virus Diseases, Epstein-Barr Virus Infections

NCT06926894 2025-07-31

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

Phase 1 Recruiting

18 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Immunologic Deficiency Syndromes, Epstein-Barr Virus Infections

NCT05011058 2025-07-28

NAVAL-1

Phase 2 Terminated

102 enrolled 28 charts

Epstein-Barr Virus Infections, Pyloric Stenosis, Hypertrophic

NCT04832607 2025-07-18

TRACE

Phase 3 Recruiting

149 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT04645147 2025-07-17

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

Phase 1 Active not recruiting

83 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT01494103 2025-07-11

DOTTI

Phase 1 Active not recruiting

15 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05592626 2025-07-09

START-001

Phase 1/2 Recruiting

365 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06027879 2025-06-25